Advertisement

Dyskinesia pp 111-117 | Cite as

Medical Treatment of Dystonia

  • H. Pakkenberg
  • B. Pedersen
Part of the Psychopharmacology Supplementum book series (PSYCHOPHARM, volume 2)

Abstract

We review dystonia treatment results since 1981, including our own findings. Anticholinergics are still the most effective drugs, but less than 50% of patients continue with treatment. The authors recommend a combination of an anticholinergic, a benzodiazepine, and another drug (an antidopaminergic, carbamazepine, or fluperlapine) for the treatment of dystonia.

Keywords

Essential Tremor Tardive Dyskinesia Tourette Syndrome Focal Dystonia Generalize Dystonia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Altrocchi PH, Forno LS (1983) Spontaneous oral-facial dyskinesia: Neuropathology of a case. Neurology 33: 802–805PubMedGoogle Scholar
  2. Burke R, Fahn S (1983) Double-blind evaluation of trihexyphenidyl in dystonia. In: Fahn S, Calne D, Shoulson I (eds) Experimental therapeutics of movement disorders. Raven, New York, pp 189–192Google Scholar
  3. Burke RE, Fahn S, Jankovic J, Marsden CD, Lang AE, Gollomp S, Ilson J (1982) Tardive dystonia and inappropriate use of neuroleptic drugs. Lancet 1: 1299PubMedCrossRefGoogle Scholar
  4. Casey DE (1980) Pharmacology of blepharospasm-oromandibular dystonia syndrome. Neurology 30: 690–695PubMedGoogle Scholar
  5. Fahn S (1983a) High-dosage anticholinergic therapy in dystonia. In: Fahn S, Calne D, Shoulson I (eds) Experimental therapeutics of movement disorders. Raven, New York, pp 177–188Google Scholar
  6. Fahn S (1983b) High dosage anticholinergic therapy in dystonia. Neurology 33: 1255–1261PubMedGoogle Scholar
  7. Faurbye A, Rasch PJ, Bender Petersen P, Brandborg G, Pakkenberg H (1964) Neurological symptoms in pharmacotherapy of psychosis. Acta Psychiatry Scand 40: 10–27CrossRefGoogle Scholar
  8. Fog R, Pakkenberg H (1970) Combined nitoman-pimozide treatment of Huntington’s chorea and other hyperkinetic syndromes. Acta Neurol Scand 46: 249–251PubMedCrossRefGoogle Scholar
  9. Garcia-Albea E, Franch O, Munoz D, Recoy JR (1981) Brueghel’s syndrome, report of a case with postmortem studies. J Neurol Neurosurg Psychiatry 44: 437–440PubMedCrossRefGoogle Scholar
  10. Gollomp SM, Fahn S, Bush R, Recher A, Ilson J (1983) Therapeutic trial in Meige’s syndrome. In: Fahn S, Calne D, Shoulson I (eds) Experimental therapeutics of movement disorders. Raven, New York, pp 207–214Google Scholar
  11. Jankovic J, Ford J (1983) Blepharospasm and orofacialcervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 13: 402–411PubMedCrossRefGoogle Scholar
  12. Lang AE, Sheehy MP, Marsden CD (1982) Anticholinergics in adult-onset focal dystonia. J Can Sci Neurol 9: 313–319Google Scholar
  13. Marsden CD (1976) Blepharospasm-oromandibular dystonia syndrome (Brueghel’s syndrome). J Neurol Neurosurg Psychiatry 37: 1204–1209CrossRefGoogle Scholar
  14. Marsden CD (1981) Treatment of torsion dystonia. In: Barbeau A (ed) Disorders of movement. MTP Press, Lancaster, pp 81–104Google Scholar
  15. Marsden CD, Fahn S (1982) Problems in dyskinesias. In: Marsden CD, Fahn S (eds) Movement disorders. Butterworth, London, pp 191–195Google Scholar
  16. Marsden CD, Lang AE, Sheehy MP (1983) Pharmacology of cranial dystonia. Neurology 33: 1100–1101PubMedGoogle Scholar
  17. Nutt JG, Hammerstad JP, Carter JH, DeGarmo P (1983) Meige’s syndrome: treatment with trihexiphenidyl. Adv Neurol 37: 201–205PubMedGoogle Scholar
  18. Obeso JA, Rothwell JC, Lange AE, Marsden CD (1983) Myoclonic dystonia. Neurology 33: 825–830PubMedGoogle Scholar
  19. Pakkenberg B, Regeur L, Fog R, Pakkenberg H (1982) Gilles de la Tourette’s syndrom. Ugeskr Laeger 144: 3078–3080PubMedGoogle Scholar
  20. Stahl SM, Berger PA (1982) Bromocriptine, physostigmine, and neurotransmitter mechanisms in the dystonias. Neurology 32: 889–892PubMedGoogle Scholar
  21. Tanner CM, Glantz RH, Klawans HL (1982) Meige’s disease: acute and chronic cholinergic effects. Neurology 32: 783–784PubMedGoogle Scholar
  22. Tolosa ES (1981) Clinical features of Meige’s disease. Arch Neurol 38: 147–151PubMedGoogle Scholar
  23. Weiner WJ, Nausieda PA (1982) Meige’s syndrome during long-term dopaminergic therapy in Parkinson’s disease. Arch Neurol 39: 451–452PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • H. Pakkenberg
  • B. Pedersen
    • 1
  1. 1.Department of NeurologyHvidovre University HospitalHvidovreDenmark

Personalised recommendations